Abstract. Decoy receptor 3 (DcR3), a decoy molecule belonging to the tumor necrosis factor receptor superfamily (TNFRSF), is a soluble receptor that can neutralize the biological effects of three other TNFSF members, namely, Fas ligand (FasL/TNFSF6/CD95L), LIGHT (TNFSF14) and TNF-like molecule 1A (TL1A/TNFSF15). DcR3 expression is increased in tumor cells. As such, DcR3 has been considered a potential biomarker to predict cancer invasion and progression of inflammation. However, the molecular mechanisms of DcR3 in tumor progression and metastasis remain poorly described. In the present study, DcR3 induced cytoskeleton remodeling, inhibited E-cadherin expression, and promoted cancer cell migration. Immunofluorescence and flow cytometry demonstrated that DcR3 expression was increased in hepatoma cells, whereas E-cadherin expression was significantly downregulated. Immunohistochemistry revealed that DcR3 and E-cadherin exhibited an opposite expression pattern between normal and cancerous liver tissues. Moreover, DcR3 treatment promoted IκBα degradation and p65 nuclear translocation. Therefore, the present study uncovered the mechanism underlying the function of DcR3 in cancer cell migration and provides evidence that DcR3 may be a potential target for cancer therapy.
Introduction
Decoy receptor 3 (DcR3), a soluble molecule belonging to the tumor necrosis factor receptor superfamily (TNFRSF), was first identified as a decoy receptor of Fas ligand (FasL) and inhibitor of FasL-induced apoptosis (1) . DcR3 also neutralizes the biological effects of two other TNFSF members, namely, LIGHT (TNFSF14) and TNF-like molecule 1A (TL1A/TNFSF15) (2-4). DcR3 can be defined as an immunomodulator on the basis of its neutralizing effects on FasL, LIGHT and TL1A (4) (5) (6) (7) . DcR3 is upregulated in tumor cells and inflammatory diseases (8) (9) (10) (11) . DcR3 in serum can be used as a biomarker to predict cancer invasion and progression of inflammation (12) (13) (14) (15) . DcR3 also acts as an effector molecule to modulate cell function through non-decoy activities, including the effects on cell adhesion and differentiation (16) (17) (18) .
Liver cancer is a common malignancy worldwide. Cancerous liver tissues yield high DcR3 expression, and this expression is correlated with tumor differentiation, serosal invasion and liver metastases (13, 19, 20) . Nevertheless, the precise mechanisms of DcR3 in liver cancer progression and metastasis remain unclear.
E-cadherin, a classical member of the cadherin superfamily, is a calcium-dependent cell-cell adhesion glycoprotein (21) . The E-cadherin-catenin complex plays a key role in cellular adhesion (22, 23) . The loss of E-cadherin function or expression has been implicated in cancer progression and metastasis (24, 25) . In the present study, DcR3 treatment caused HepG2 cell cytoskeleton remodeling, inhibited E-cadherin expression, and promoted cell migration. Immunohistochemical analysis revealed that E-cadherin and DcR3 exhibited an opposite expression trend in liver carcinoma tissues. The present study also demonstrated the functional mechanism of DcR3 in cancer cell migration and provides a theoretical basis for the use of a DcR3 antagonist to treat liver cancer. Western blot analysis. Hepg2 cells were treated with 3 µg/ml DcR3-Fc or Igg1 as control, or transfected with the indicated plasmids. At 48 h after transfection or treatment, cells were harvested and determined by the antibodies indicated in the figures. Cell pellets were lysed in RIPA (Thermo Fisher Scientific Inc., Waltham, MA, USA), 1 mM phenylmethylsulfonyl fluoride (PMSF) (Beyotime, Shanghai, China) and 1% protease inhibitor cocktail (Thermo Fisher Scientific, Inc.). Lysates were normalized for total protein (25 µg) and loaded on 8-12% sodium dodecyl sulfate-polyacrylamide gel, electrophoresed, and transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Kenilworth, NJ, USA), followed by blocking with 5% skimmed milk at room temperature for 1 h. The membrane was incubated with primary antibodies overnight at 4̊C, and rinsed with Tris-buffered saline with Tween-20. The blots were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (KPL) for 1 h at room temperature. Detection was performed using EMD Millipore Luminata™ Western HRP Chemiluminescence Substrates (WBLuR0500). Nuclear and cytoplasmic extracts were isolated with NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (78833) purchased from Thermo Fisher Scientific. The defined sections of the film were scanned for image capture and quantification using Adobe Photoshop software (CS4; (Adobe Systems, Inc., San Jose, CA, USA) and ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Materials and methods

Clinical
RNA isolation and real-time quantitative PCR. Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were reverse transcribed with oligo (dT) and M-MLV Reverse Transcriptase (Takara, Tokyo, Japan). A mixture of 1 µg RNA, 4 µl 5x RT mix, 1 µl primer mix, and nuclease-free water were made up to a 20-µl volume. The reverse transcription step was as follow: 37̊C for 15 min; 85̊C for 5 sec, and then stored at -20˚C. Realtime quantitative PCR analysis was performed with specific primers for human E-cadherin (forward, 5'-TggAggAATTC TTGCTTTGC-3' and reverse, 5'-CGTACATGTCAGCCAGC TTC-3') in a CFx96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) with SYBR qPCR mix (Takara). Relative levels of gene expression were determined using gAPDH as the control (forward, 5'-ATCTggCACCAC ACCTTCTAC-3' and reverse, 5'-CAGCCAGGTCCAGACGC Agg-3'). SYBR-green PCR Master Mix 2 µl, forward and reverse primers 200 nM, cDNA template 100 ng, and ddH 2 O up to 10 µl volume was mixed together. PCR conditions consisted of the following: 95̊C for 3 min for denaturation; 95̊C for 5 sec for annealing; and 60̊C for 40 sec for extension, for 40 cycles. The threshold cycle for each sample was selected from the linear range and converted to a starting quantity by interpolation from a standard curve generated on the same plate for each set of primers. The E-cadherin mRNA levels were normalized for each well to the gAPDH mRNA levels using the 2 -ΔΔCt method.
Immunofluorescent assay. L02 or Hepg2 cells were washed with phosphate-buffered saline (PBS) and fixed at room temperature with 4% polyformaldehyde for 10 min, permeated with 0.1% Triton x-100 for 7 min, blocked for 30 min with 1% BSA, and incubated sequentially with the indicated primary and secondary antibodies. 4',6-Diamidino-2-phenylindole (DAPI) (Beyotime) was used to label the nuclei. PhalloidinRhodamine (Thermo Fisher Scientific) was used for F-actin staining. Immunochemistry. The sample sections were deparaffinized and rehydrated. After boiling in a microwave oven, the antigen was retrieved with a 0.01 M sodium citrate buffer (pH 6.0) at a sub-boiling temperature for 20 min. The following steps were performed with the SP kit (9001; ZSgB-BIo, Beijing, China). Shortly, the sections were incubated with 3% hydrogen peroxide for 10 min to block endogenous peroxidase. After 15 min of pre-incubation in 5% normal goat serum to prevent non-specific staining, the samples were incubated with the antibody to DcR3 (Abcam, Cambridge, UK) at 4̊C overnight. Secondary antibody was added and incubated for 30 min. The sections were incubated in horseradish enzyme-labeled chain avidin solution for 30 min at room temperature. Color was developed with a diaminobenzidine (DAB) substrate kit. Counterstaining was performed with hematoxylin.
Wound healing assay. Confluent cell cultures were grown on 6-well plates. Wounds were made with the tip of a micropipette. DcR3-Fc was added to the culture medium at a final concentration of 3 µg/ml. Igg1 was added as a control. Wound closure speed was analyzed as indicated in the legend.
Transwell assay. Hepg2 cells were treated with 3 µg/ml DcR3-Fc or Igg for 24 h, and then were trypsinized and resuspended in DMEM without FBS before plating on the upper layer of the Transwell with an 8-µm pore-size membrane at a cell density of 1x10 4 . DMEM containing 5% FBS was added to the lower layer. After 15 h, the cells remaining on the top surface were scratched off. The cells on the lower surface were fixed in methanol, stained with 0.5% crystal violet (Beyotime), and images were captured under a microscope. The intact Transwell was dissolved in 33% acetic acid, and the supernatant was detected for absorption values with a spectrophotometer at 590 nm.
Materials. DcR3-Fc and human Igg1 proteins were purchased from Sino Biological, Inc. (Beijing, China). Anti-DcR3, anti-E-cadherin and anti-IκBα antibodies were purchased from Abcam. Anti-p65 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-tubulin was purchased from Abmart (Shanghai, China).
Statistical analysis. All experiments were repeated at least three times or noted otherwise. Data are expressed as mean ± SD. The t-test was performed for inter-group comparisons. Values with p<0.05 were considered to show significant differences.
Results
DcR3 regulates colony scattering of HepG2 cells and decreases E-cadherin expression.
Hepg2 cells were examined using a colony scattering assay to analyze the function of DcR3 in regulating cell migration. The colony scattering assay, mimicking certain aspects of tumor invasion, reveals the ability of epithelial tumor cells to detach from colonies in culture. The cells were plated at very low density, and the morphological characteristics of the colonies were evaluated 5 days after plating. The colonies were compact in the control or Igg1 groups, and >90% of the cells in a colony contained cell-cell junctions. By contrast, the cells were scattered in the DcR3 treatment group, and <20% of the cells formed junctions (Fig. 1A) . In the cells detached from the scattered colonies, numerous protrusions were formed on the membrane edge of these cells (Fig. 1A, lane 3, arrows) . Philloidin staining revealed that DcR3 promoted actin remodeling and revealed a scattered phenotype (Fig. 1B) . This finding indicated that DcR3 triggered changes in cell morphology and enhanced the ability of cells to detach from the colonies.
DcR3 treatment disrupts colony scattering and causes cytoskeleton remodeling in HepG2 cells. To investigate the role of DcR3 in the regulation of cell-cell adhesion, we detected whether E-cadherin, a key molecule in the regulation of intercellular adhesion, was regulated by DcR3. The mRNA of E-cadherin was significantly downregulated by DcR3 treatment (Fig. 1C) . The same effect was observed at the protein level (Fig. 1D ). DcR3 expression also inhibited E-cadherin expression (Fig. 1E) . Thus, DcR3 is a negative regulator of E-cadherin. the significance of the role of DcR3 in hepatocarcinoma, we detected DcR3 and E-cadherin expression levels in the normal liver cell line L02 and the hepatoma cell line HepG2 by performing immunofluorescent assays. The DcR3 expression level was higher in the Hepg2 cells than that noted in the L02 cells (Fig. 2A) . To confirm this observation, we detected the DcR3 expression using flow cytometry. The DcR3 expression level in Hepg2 cells was higher than that in the L-02 cells (Fig. 2B ). Protein and mRNA quantification showed that E-cadherin was downregulated in the Hepg2 cells as compared with that in the L-02 cells (Fig. 2C and D) . Importantly, immunohistochemical staining showed that DcR3 was almost undetectable in the non-tumor liver tissues (from patients with biliary tract disease) but was upregulated in the liver cancer tissues (Fig. 2E) . Inversely, E-cadherin was located in the cell junction in non-tumor tissue, but was almost undetectable in liver cancer tissue (Fig. 2F) . Therefore, hepatocarcinomas exhibited low E-cadherin expression but high DcR3 levels.
DcR3 and E-cadherin expression levels are inversely correlated in hepatocarcinoma cell lines and tissues. To understand
DcR3 promotes cancer cell migration.
Considering that E-cadherin plays a crucial role in cell adhesion and migration, we analyzed the effect of DcR3 on the migratory ability of Hepg2 cells. The wound healing assay demonstrated that the addition of the DcR3-containing supernatant caused a strong increase in cell migration at 24 and 48 h (Fig. 3A and B) . To confirm this trend, we detected the cell migratory ability using a Transwell assay. We observed that DcR3 greatly enhanced HepG2 cell migration (Fig. 3C-E) . These results also indicated that DcR3 plays a positive role in cancer cell migration.
DcR3 induces p65 cytoplasm-nuclear translocation.
To investigate whether DcR3 inhibits E-cadherin expression via its decoy function, we treated Hepg2 cells by simultaneously adding DcR3 and its ligand FasL, LIGHT or TL1A, to the culture medium. The addition of these ligands did not affect the function of DcR3 in the regulation of E-cadherin expression (Fig. 4A) . Thus, DcR3 inhibited E-cadherin expression via its non-decoy function.
To investigate the mechanism of the function of DcR3 in E-cadherin regulation, we explored the involved signaling pathway. DcR3 regulates the NFκB signaling pathway in monocytes. E-cadherin is also a target of p65 (26, 27) . Consequently, we investigated whether DcR3 activates NFκB signaling in Hepg2 cells. DcR3 significantly downregulated IkBα expression (Fig. 4B) . Furthermore, DcR3 treatment of HepG2 cells markedly increased the nuclear translocation of the NF-κB subunit p65 (Fig. 4C) . These data suggest that the NFκB signaling cascade is an essential component in the involvement of E-cadherin expression for the DcR3-mediated migration response.
Discussion
DcR3 can be defined as a novel immunosuppressant on the basis of its neutralizing effects on FasL, LIGHT and TL1A. DcR3 is expressed by tumor cells from various lineages, including adenocarcinomas of the colon, rectum (28, 29) , lung (30) and gastric cancer (31) , hepatocellular carcinoma (13, 20) and in chronic liver diseases (19) , which frequently lead to cancer formation. Increased DcR3 levels in serum or tissues were found to be correlated with poor prognosis and resistance to treatment in some cancer patients (13) . In addition to its neutralizing effect, DcR3 also acts as an effector molecule to modulate cell function via non-decoy activities, including the regulation of DC and macrophage differentiation that leads to Th2 polarization (32, 33) , M2 macrophage differentiation (34) , and cytoskeleton remodeling (16, 17) .
DcR3 can induce actin reorganization in human monocytes, and this protein triggers multiple signaling molecules, such as PKC and phosphatidylinositol 3-kinase (PI3K) (35) . Furthermore, DcR3 induces NFκB-mediated expression of ICAM-1, VCAM-1 and IL-8 by monocytes; consequently, their binding to endothelial cells is enhanced (17) . DcR3-Fc was found to act on THP-1 monocytes and differentiated macrophages to increase the expression level of integrin α4. Thus, cell aggregation and proliferation are promoted and apoptosis is reduced (18) . DcR3 is upregulated in cancer cells; thus, these observations suggest its important roles in modulating the migration and trafficking of monocytes/macrophages in the tumor microenvironment.
E-cadherin plays an important role in cell adhesion by forming adherent junctions to bind cells within tissues. The loss of E-cadherin expression has been defined as a hallmark of EMT. EMT is a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and they gain migratory and invasive properties to become mesenchymal stem cells. DcR3 was found to induce IκB kinase activation, IκB degradation, and p65 nuclear translocation in human microvascular endothelial cells (17) . E-cadherin is a target of p65, which represses E-cadherin expression and enhances the epithelialto-mesenchymal transition of mammary epithelial cells via ZEB-1 and ZEB-2 (36) . In addition, TGF-β is one of the most critical factors involved in EMT regulation. TgF-β promotes EMT through both Smad-dependent and Smad-independent manner (37) . The relationship between DcR3 and the TgF-β pathway will be the research of interest in a future study. A model of the function of DcR3 in cell migration regulation is shown in Fig. 4D . DcR3 controls the expression of E-cadherin and the p65 translocation of HepG2 cells. Thus, it elicits double effects in tumor metastasis regulation and immune modulation. The blocking of DcR3 may be applied as an effective therapeutic strategy to prevent tumor metastasis.
In conclusion, the present study demonstrated that DcR3 is overexpressed in hepatic carcinoma tissues and cell lines. DcR3-Fc treatment inhibited E-cadherin expression, enhanced tumor cell migration in vitro, and promoted p65 nuclear translocation. These findings revealed the mechanism underlying the ability of DcR3 to regulate cell migration. Therefore, DcR3 may be a potential target for the gene therapy of hepatic carcinoma.
